Location History:
- Aberdeenshire, GB (2024)
- Aberdeen, GB (2024)
Company Filing History:
Years Active: 2024-2025
Title: Obinna Chukwuemeka Ubah: Innovator in Specific Binding Molecules
Introduction
Obinna Chukwuemeka Ubah is an accomplished inventor based in Aberdeenshire, GB, known for his contributions to the field of biochemistry and molecular biology. With a total of three patents, Ubah has made significant strides in developing specific binding molecules that have implications for medical science and therapeutic applications.
Latest Patents
His latest patents focus on innovative advancements in the formation of multi-domain specific binding molecules derived from Variable New Antigen Receptor (VNAR) technology. The first patent details the creation of these binding molecules, particularly those that bind to Tumour Necrosis Factor alpha (TNFα), which plays an important role in inflammatory responses. The second patent introduces a synthetic library of humanized antigen-specific binding molecules, utilizing species from the Elasmobranchii subclass. This invention emphasizes processes for production and highlights the importance of humanized Ig-like VNARs in therapeutic contexts.
Career Highlights
Obinna Chukwuemeka Ubah works with Elasmogen Limited, a company recognized for its cutting-edge research in the field of therapeutic proteins. His work demonstrates a commitment to advancing biotherapeutic solutions that can combat various diseases, particularly those involving inflammatory pathways.
Collaborations
At Elasmogen Limited, Ubah collaborates with distinguished colleagues, including Caroline Barelle and Andrew Porter. Together, they contribute to a collaborative environment where innovative ideas flourish and lead to groundbreaking discoveries in the field of binding molecules.
Conclusion
Obinna Chukwuemeka Ubah's innovative approach to specific binding molecules exemplifies the impactful role of inventors in advancing science and medicine. His patents showcase not only his expertise but also the potential applications of his work in therapeutic settings. As he continues to push the boundaries of innovation at Elasmogen Limited, the scientific community eagerly anticipates his future contributions.